Copyright
©The Author(s) 2015.
World J Diabetes. Jun 25, 2015; 6(6): 840-849
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.840
Published online Jun 25, 2015. doi: 10.4239/wjd.v6.i6.840
Table 4 Efficacies of both monotherapies and combination therapies with dipeptidase-4 inhibitors
| Ref. | Study duration (mo) | n | DPP-4 inhibitor | Treatment dose (mg) | Combination therapy | Parameter (%) | Pre-treatment | Post-treatment | Efficacy |
| Ito et al[12] | 6 | 30 | Vildagliptin | 50 or 100 | Mitiglinide and/or voglibose | HbA1c | 6.7 | 6.1 | -0.6 |
| GA | 24.5 | 20.5 | -4.0 | ||||||
| Fujii et al[16] | 12 | 30 | Alogliptin | 6.25 | Mitiglinide and/or voglibose | HbA1c | 7.2 | 6.3 | -0.9 |
| GA | 25.6 | 20.7 | -4.9 | ||||||
| Nowicki et al[17] | 12 | 19 | Saxagliptin | 2.5 | Unknown | HbA1c | 8.7 | 7.5 | -1.2 |
| GA | Unknown | Unknown | Unknown |
- Citation: Nakamura Y, Hasegawa H, Tsuji M, Udaka Y, Mihara M, Shimizu T, Inoue M, Goto Y, Gotoh H, Inagaki M, Oguchi K. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes 2015; 6(6): 840-849
- URL: https://www.wjgnet.com/1948-9358/full/v6/i6/840.htm
- DOI: https://dx.doi.org/10.4239/wjd.v6.i6.840